
While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.